Ron Philip was appointed Director of Avalo Therapeutics, Inc., effective June 23, 2026. As of November 7, 2026, Avalo Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 12, 2026 to June 23, 2026, naming 1 appointment (Form 8-K, June 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Avalo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avalo Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-12 to 2026-06-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Avalo Therapeutics, Inc. files it.
Also on the record for Avalo Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 0.9% of the class | 5%+ stakes | Source |
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.8% of the class | 5%+ stakes | Source |
| October 29, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 4.44% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Caligan Partners LP | 5.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.87% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 3.54% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 6.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | — | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 5.5% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Avalo Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Avalo Therapeutics, Inc. and the records around it.
Avalo Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Patrick J. Crutcher also filed stake reports on 1 other company: IBIO, INC. (Jul 2025)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
- Caligan Partners LP also filed stake reports on 9 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Opus Genetics, Inc. (Aug 2026)
Watch Avalo Therapeutics, Inc.
Get an email when Avalo Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avalo Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Avalo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avalo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 59 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-23 | In | Director | 2026-06-23 | 8-K, 2026-06-23 | |
| 2026-06-12 | Reported | not named in the filing | 8-K, 2026-06-12 |
Who leads Avalo Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Ron Philip, appointed, effective 2026-06-23 (filed 2026-06-23).
New leaders reset buying decisions — get the Full Report on Avalo Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Avalo Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Avalo Therapeutics, Inc.Every change, in the filing's words
Appointed: Ron Philip, Director, effective 2026-06-23
On June 23, 2026, the board of directors (the " Board ") of Avalo Therapeutics, Inc. (the " Company ") appointed Ron Philip to the Board, effective June 23, 2026.
- Mr. Philip will serve as a director until the Company's 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified.
- Mr. Philip will serve as a member of the Compensation Committee and Science, Development and Commercial Advisory Committee immediately upon his appointment.
- Mr. Philip will be eligible for Board compensation pursuant to the Company's Amended and Restated Non-Employee Director Compensation Plan (the "A&R Non-Employee Director Compensation Plan").
- Accordingly, in connection with his appointment and in accordance with the A&R Non-Employee Director Compensation Plan, Mr. Philip will be granted a non-qualified stock option award to purchase 40,200 shares of the Company's common stock on June 23, 2026, vesting in three substantially equal installments on the first, second and third anniversary of the date of grant, in each case, subject to his continued service on each such vesting date.
- The option has an exercise price equal to the closing price of the Company's common stock on the Nasdaq Capital Market on June 23, 2026.
Reported
In addition, consistent with the terms of the employment agreements prior to the Employment Agreement Amendments and solely with respect to options granted prior to the Effective Date, such options will vest in full as of such termination, and all vested options held as of the date of termination will remain exercisable thereafter for a period of twelve (12) months in the case of Dr. Neil and Mr. Sullivan and six (6) months in the case of Dr. Doyle and Mr. Boyd.
- On June 12, 2026 (the "Effective Date"), the Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company's Chief Executive Officer, Christopher Sullivan, the Company's Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company's Chief Medical Officer and Taylor Boyd, Chief Business Officer (together, the "Employment Agreement Amendments").
- The Employment Agreement Amendments amend the provisions of the employment agreements with each of Dr. Neil, Mr. Sullivan, Dr. Doyle and Mr. Boyd that relate to potential payments and benefits in connection with certain employment terminations and a change in control.
- The payments pursuant to clauses (i)-(ii) will be made promptly after the closing of the Change in Control or his or her termination, whichever is later.
Tools for this story
Each opens in a new tab, filled in for Avalo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.